Morgan Stanley: Coherent's prospects "disappointing" Target price lowered to $89.
Morgan Stanley lowered Coherent's target stock price, calling the outlook "disappointing".
Morgan Stanley has lowered its target price for Coherent (COHR.US) from $97 to $89 and maintains a "hold" rating. According to analysts, the fourth-quarter earnings exceeded Wall Street expectations, but the company's outlook is "disappointing." Especially considering that the company's stock rose by 20% last month, and the performance reports of other artificial intelligence-related companies have raised market expectations, this situation is more prominent. Morgan Stanley believes that the stock may still "be in a neglected state" at the moment.
Related Articles
BOSS ZHIPIN-W(02076): Chen Xu is appointed as the President of the Company.
SINOPHARM (01099): China National Medicines Corporation (600511.SH) reported a net profit attributable to shareholders of 949 million yuan in the first half of the year, a decrease of 5.19% compared to the same period last year.
JOIN-SHARE(01543): "2201" will pay interest on August 22nd.
BOSS ZHIPIN-W(02076): Chen Xu is appointed as the President of the Company.
SINOPHARM (01099): China National Medicines Corporation (600511.SH) reported a net profit attributable to shareholders of 949 million yuan in the first half of the year, a decrease of 5.19% compared to the same period last year.
JOIN-SHARE(01543): "2201" will pay interest on August 22nd.
